PDS Biotech announces colorectal cancer cohort of Phase 2 clinical trial with PDS01 ADC met criteria for expansion to stage 2 following positive stage 1 results

CAR-T Digest - August 2020

Weekly Digest - July 2025

10 July 2025: PDS Biotech announces colorectal cancer cohort of Phase 2 clinical trial with PDS01 ADC met criteria for expansion to stage 2 following positive stage 1 results

PDS Biotech’s Phase 2 trial of PDS01ADC for metastatic colorectal cancer, in combination with floxuridine via hepatic artery infusion, in stage 1, triggering expansion to stage 2 enrollment
At least 6 of 9 patients in the colorectal cancer cohort showed objective responses, allowing the cohort to progress toward full enrollment of 22 participants
PDS01ADC is a novel IL-12–based antibody-drug conjugate that targets necrotic tumor regions with minimal systemic IL-12 exposure, aiming to reduce toxicity while enhancing immune activation